BBIO (BridgeBio Pharma, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-08-18 | Maricel Apuli | Chief Accounting Officer | F | — | — |
| 2026-08-18 | Thomas Trimarchi | President and CFO | F | — | — |
| 2026-08-18 | Neil Kumar | Chief Executive Officer | MIXED | — | — |
| 2026-08-03 | Maricel Apuli | Chief Accounting Officer | Sell | — | — |
| 2026-07-13 | Andrea Ellis | Director | MIXED | — | — |
| 2026-07-13 | Jennifer E. Cook | Director | MIXED | — | — |
| 2026-06-24 | JAMES C MOMTAZEE | Director | A | — | — |
| 2026-06-24 | Andrea Ellis | Director | A | — | — |
| 2026-06-24 | Hannah Valantine | Director | MIXED | — | — |
| 2026-06-24 | Fred Hassan | Director | A | — | — |
| 2026-06-24 | Andrew Lo | Director | A | — | — |
| 2026-06-24 | Ali J. Satvat | Director | A | — | — |
| 2026-06-24 | Douglas A. Dachille | Director | A | — | — |
| 2026-06-24 | ERIC AGUIAR | Director | A | — | — |
| 2026-06-24 | RONALD J DANIELS | Director | A | — | — |
| 2026-06-24 | FRANK MCCORMICK | Director | A | — | — |
| 2026-06-24 | CHARLES J HOMCY | Director | A | — | — |
| 2026-06-24 | Jennifer E. Cook | Director | MIXED | — | — |
| 2026-06-23 | CHARLES J HOMCY | Director | F | — | — |
| 2026-06-17 | Jennifer E. Cook | Director | MIXED | — | — |
| 2026-06-08 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-05-26 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-05-19 | Randal W. Scott | Director | MIXED | — | — |
| 2026-05-19 | Maricel Apuli | Chief Accounting Officer | F | — | — |
| 2026-05-19 | Neil Kumar | Chief Executive Officer | MIXED | — | — |
| 2026-05-19 | Thomas Trimarchi | President and CFO | MIXED | — | — |
| 2026-05-11 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-05-04 | Maricel Apuli | Chief Accounting Officer | Sell | — | — |
| 2026-04-13 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-03-20 | Maricel Apuli | Chief Accounting Officer | A | — | — |
| 2026-03-20 | Thomas Trimarchi | President and CFO | A | — | — |
| 2026-03-19 | Neil Kumar | Chief Executive Officer | A | — | — |
| 2026-03-16 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-03-12 | Hannah Valantine | Director | MIXED | — | — |
| 2026-03-06 | Andrea Ellis | Director | MIXED | — | — |
| 2026-03-03 | Hannah Valantine | Director | MIXED | — | — |
| 2026-02-27 | Maricel Apuli | Chief Accounting Officer | Sell | — | — |
| 2026-02-23 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-02-18 | Maricel Apuli | Chief Accounting Officer | MIXED | — | — |
| 2026-02-18 | Randal W. Scott | Director | MIXED | — | — |
| 2026-02-18 | Neil Kumar | Chief Executive Officer | MIXED | — | — |
| 2026-02-18 | Thomas Trimarchi | President and CFO | MIXED | — | — |
| 2026-02-12 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2026-01-12 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| 2025-12-16 | Thomas Trimarchi | President and CFO | F | — | — |
| 2025-12-16 | Maricel Apuli | Chief Accounting Officer | F | — | — |
| 2025-12-16 | Neil Kumar | Chief Executive Officer | MIXED | — | — |
| 2025-12-10 | Maricel Apuli | Chief Accounting Officer | Sell | — | — |
| 2025-12-08 | Neil Kumar | Chief Executive Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 34,510,971 | — |
| — | 10%+ Owner | 26,620,991 | — |
| — | 10%+ Owner | 25,260,971 | — |
| — | 10%+ Owner | 25,120,991 | — |
| — | 10%+ Owner | 19,260,971 | — |
| — | 10%+ Owner | 18,555,375 | — |
| — | 10%+ Owner | 13,260,971 | — |
| — | 10%+ Owner | 11,736,137 | — |
| — | Director | 919,876 | — |
| — | Director | 767,244 | — |
| — | Chief Executive Officer | 764,814 | — |
| — | President and CFO | 336,529 | — |
| — | Chief Business Officer | 274,211 | — |
| — | Director | 169,983 | — |
| — | Chief Accounting Officer | 122,687 | — |
| — | CFO and Treasurer | 110,964 | — |
| — | Director | 99,070 | — |
| — | Director | 68,662 | — |
| — | Director | 55,126 | — |
| — | Director | 39,746 | — |
| — | See Remarks | 32,068 | — |
| — | Director | 30,579 | — |
| — | Director | 29,879 | — |
| — | Director | 27,383 | — |
| — | Chief Operating Officer | 24,615 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BBIO quote page; the site-wide leaderboard is on the insider transactions hub.